StockGlow

Eledon Pharmaceuticals, Inc. (ELDN)

Develops antibody drugs to prevent organ rejection after transplants and treat ALS.

$3.40-0.05%Healthcare
Compare ELDN with
StockGlow Score
70
Leaning Bullish
BearishBullish
1 year ago+0.6%

The outlook

ELDN trades at $3.40 and sits roughly midway in its 52-week range. Analyst coverage shows an average price target about 165% above the current level, reflecting optimism among researchers. The stock's technical positioning is mixed relative to its moving averages, while sentiment leans bullish overall.

What’s behind the score

Price trendMixed vs its moving averages
52-week range63% of the way from its 52-week low to high
Price targetAvg target +165% vs current price

Analyst price target

~12-month · 5 analysts
$9.00average target+164.7% vs now
Now $3.40
Low $7.00High $12.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$262.4M
52-wk high
$4.60
52-wk low
$1.35
50-day avg
$3.77
200-day avg
$2.89
Trailing P/E
—

Similar stocks

ABOSAcumen Pharmaceuticals, Inc.$2.28+3.64%TARAProtara Therapeutics, Inc.$3.94-2.48%LRMRLarimar Therapeutics, Inc.$3.83+0.00%RZLTRezolute, Inc.$4.92-0.40%ALGSAligos Therapeutics, Inc.$4.25+4.17%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy